Navigation Links
Blocking crucial molecule could help treat multiple sclerosis, Jefferson neuroscientists say
Date:4/24/2011

ars in an advance online publication of Nature Immunology on April 24.

These findings identify the interleukin-23 (IL-23)/ Th17/GM-CSF axis as the major pathway in pathogenesis of autoimmune central nervous system inflammation and likely other autoimmune diseases. IL-23, a known cytokine that causes autoimmune inflammation of the brain, induces production of more GM-CSF in Th17 cells, the researchers explain.

Dr. Rostami, who is also director of the Neuroimmunology Laboratory in the Department of Neurology at JMC, and his colleagues used an animal model of MS called experimental autoimmune encephalomyelitis (EAE) for the investigation, a common model used to study the pathogenesis of the disease. Mice whose Th17 cells cannot produce GM-CSF did not develop neuroinflammation, thus GM-CSF is responsible for disease manifestation in this experimental model. This scenario suggests feed-forward loop of IL-23 and GM-CSF driving the pathogenic encephalitogenic immune response in the brain and spinal cord.

Another recently published paper in Nature Immunology by Dr. Rostami and his team unraveled a mechanism that may help fight MS. The researchers found that a protein known as interkeukin-27 (IL-27) helped block, not induce, the onset of symptoms in animals with an MS-like disease. While increasing levels of GM-CSF may cause the disease, as shown in the current paper, increasing IL-27 concentrations may help quell an over-active immune system, the researchers reported.

"That was the first time that we had direct evidence that by actively giving IL-27 like a drug, we can suppress EAE in mice," Dr. Rostami said.

If similar findings from this current study of GM-CSF are found in human blood samples, this approach could eventually also be shown to be useful in the clinical setting, Dr. Rostami explains.

Whether GM-CSF drives neuroinflammation in MS remains unknown, but the current findings highlight the potential t
'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
2. Blocking cell movement for cancer, MS treatment
3. Blocking cancer in its path: New cellular defect discovered
4. How blocking the Programmed Death 1 protein may treat or prevent sepsis and severe infection
5. Cranberry juice shows promise blocking Staph infections
6. Tiny RNA molecules control labor, may be key to blocking premature birth
7. Blocking the critical structure that lets cancer cells move -- their feet
8. Blocking rogue gene could stop the spread of most cancers
9. Hidden infections crucial to understanding, controlling disease outbreaks
10. Mayo researchers identify dangerous two-faced protein crucial to breast cancer spread and growth
11. In lung cancer, silencing one crucial gene disrupts normal functioning of genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blocking crucial molecule could help treat multiple sclerosis, Jefferson neuroscientists say
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... A new study presages a real aim of genetics: to ... of individual genetic variants for individual health. The research team, ... six novel genetic variants that are associated with lipid levels, ... power of ,genetic microscopes, has increased because the methods are ...
... Mass. Dec. 3, 2008 Interleukin-12 is a ... the human immune system. Having either too much or ... development of many diseases, including some cancers and auto-immune ... modulating interleukin-12 levels could yield new therapies for those ...
... Babraham Institute near Cambridge, supported by the Alzheimer,s ... Research Council (BBSRC), have discovered that the brain,s ... of ageing such as Alzheimer,s disease. The findings ... . Alzheimer,s disease causes nerve cells in ...
Cached Biology News:The genetic heart of the lipids 2The genetic heart of the lipids 3Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 2Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 3Maintaining the brain's wiring in aging and disease 2
(Date:5/4/2015)... 2015 /PRNewswire/ - JSS Medical Research Inc., a Montreal ... concluded the acquisition of Max Neeman International (MNI), with head office ... are located in Ahmedabad, Bangalore , ... US subsidiary, a regional office is located North Carolina, ... by the recent equity investment transaction into JSS with Capital Croissance ...
(Date:5/4/2015)... Israel , May 4, 2015  Tikcro Technologies ... its annual report on Form 20-F for the fiscal ... and Exchange Commission ("SEC"). The annual report on Form ... development of antibodies in the area of cancer immune ... superior qualities of high specificity and binding in targeting ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... its partners are pleased to announce the formation ... focussed on developing treatments for cancer that harness ... company represents a unique collaboration between the Children,s ... (CHEO) Research Institute, McMaster University, the Ontario Institute ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
Breaking Biology Technology:JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... NV,(Euronext Brussels: THR), a biotechnology company focused on ... it has completed,patient enrolment for its Phase II ... is to evaluate the safety and preliminary efficacy ... four and twelve hours after the onset of ...
... 8, 2008 Dendreon Corporation,(Nasdaq: DNDN ) ... registered direct offering of 8.0 million shares of ... 8.0 million shares of its common,stock. Net proceeds ... Markets LLC served as sole placement agent for ...
... Ganeden Biotech,announced that Sustenex(TM), its all-natural daily ... capsule contains at least 2,billion live probiotic ... Bacillus coagulans designed to help promote immune ... designed to survive and,thrive in the digestive ...
Cached Biology Technology:ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 3
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... off the clot from fasted Cynomolgus monkeys of mixed ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
adult...
Biology Products: